22 slides from Insight Molecular Diagnostics's investor presentation, Aug 21, 2023
Slide 1: Oncocyte Investor Presentation
Oncocyte Investor Presentation NASDAQ: OCX Josh Riggs CEO Q2 2023
Slide 2: Forward Looking Statement
Forward Looking Statement Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, amo
Slide 3: Oncocyte Investor Summary
Oncocyte Investor Summary 3 novel precision diagnostic tests for oncology - Differentiated, capital-light commercial model focused on profitability, not just revenue - Competitive proprietary, patented technologies and transplant, and published clinical data representing a - Potential disruption of
Slide 4: Differentiated Strategy Focused on Profitability
Differentiated Strategy Focused on Profitability
Slide 5: Oncocyte Diagnostic Product Market Opportunity
Oncocyte Diagnostic Product Market Opportunity Three novel diagnostic tests addressing large reimbursed markets Transplant Oncology Is the transplanted organ Will patient benefit from Is the immunotherapy drug damaged? immunotherapy? working? $500M est. revenue currently $1.5B est. revenue generated
Slide 6: Differentiated, Capital-light Commercial Model
Differentiated, Capital-light Commercial Model Development and commercial model optimized for speed to market, product margin, and capital efficiency Development Commercial Service Lab Kitted Product • Clinical development • Strategic partner distributes product • Publications • Product carries 70-1
Slide 7: Diagnostic Development and Commercialization
Diagnostic Development and Commercialization Kitted products are packaged and distributable globally Traditional Model Oncocyte Approach Selling a central lab service to physicians Selling a high-margin kitted product to existing labs Large Small Sales Sales - Kitted product Force - No scale economi
Slide 8: Transplant Central Lab Service Example
Transplant Central Lab Service Example Transplant centers have volume and capability just missing the technology Highly Concentrated Market High Capability Labs <100 transplant centers in US market Most transplant centers are in academic generate approx. 80% of the volume settings with sophisticated
Slide 9: Oncocyte Going Forward
Oncocyte Going Forward $20 – 30M - Our service lab infrastructure remains lean, supporting reimbursement and clinical Anticipated breakeven development at modest revenue - Partners share costs of commercializing our distributable kitted product - High-margin, low-complexity business model based on p
Slide 10: Product Spotlight
Product Spotlight MONCOCYTE Where Tomorrow LIVES
Slide 11: For cause testing example
For cause testing example PROBLEM: SOLUTION: Current Standard All patients newly of Care performs Elevated Liver/Kidney transplanted and being Elevated Liver/Kidney biopsies on patients Function Tests monitored for rejection Function Tests that may not need one are eligible for VitaGraft leading to
Slide 12: Detect organ damage to avoid unnecessary biopsies
Detect organ damage (e.g. rejection) to avoid unnecessary biopsies Problem Solution TAM Commercial Status Biopsies to check VitaGraft is a blood $500M est. revenue Early access program organ health post- test that is comparable currently generated by active at Nashville Lab transplantation are to bi
Slide 13: Transplant - High Demand, Fast Growing Space
Transplant - High Demand, Fast Growing Space • Central service lab competitors currently generating $500M in annual revenue from kidney & heart transplant tests • Highly litigious market limits new market entrants • Labs without an IP position are limited, generating Planned VitaGraft demand to lice
Slide 14: Clinical Data spotlight
Clinical Data spotlight Copies per mL is a more stable measurement over time, a natural advantage VitaGraft has over competing technology. Fractional measurement can create false positives the further a patient is from transplantation. Over time total cfDNA decreases As cfDNA decreases, % measuremen
Slide 15: Late-stage cancer therapy is a $100B decision that is only getting more complicated
+ Late-stage cancer therapy is a $100B decision that is only getting more complicated • Combines three elements of the tumor micro- • Blood test, uses common tumor biology, copy environment into one easy to interpret score number variation, to identify response to • Competitors currently generating
Slide 16: Next Steps
MONCOCYTE Where Tomorrow LIVES
Slide 17: Recent Accomplishments Slide
Recent Accomplishments Slide Approx 50% reduction Pivoted and focused in operating expense company strategy Sold unprofitable DetermaIO submission product line: DetermaRx for reimbursement in December 2022 Financial Highlights - $12.4M on hand at end of Q1 Clinical Development - $13.8M funding in Q2
Slide 18: Four Quarter Look-Forward
Four Quarter Look-Forward Rapid progress on milestones and market access - Manufacturing - Pre-market activities - Commercialization - Kit development - SWOG Study - NSCLC Study - Kit development 18 NASDAQ: OCX
Slide 19: 2H 2023 Major Milestone Opportunities
2H 2023 Major Milestone Opportunities Achieve reimbursement - Complete - Complete coverage for: manufacturing DetermaIO pivotal conversion of 862 patient study in VitaGraft into a triple negative kitted product breast cancer - Announce a - Commercial launch strategic or of VitaGraft Kidney distribut
Slide 20: Experienced Leadership Team
Experienced Leadership Team Pioneering Molecular Diagnostics JOSH RIGGS EKKEHARD SCHÜTZ, YUH-MIN (JOHNSON) President & Chief MD, PHD, FAACC CHIANG, PHD Executive Officer Chief Science Officer Chief Technology Officer 20 NASDAQ: OCX
Slide 21: Oncocyte Investor Summary
Oncocyte Investor Summary 3 novel precision diagnostic tests for oncology - Differentiated, capital-light commercial model focused on profitability, not just revenue - Competitive proprietary, patented technologies and transplant, and published clinical data representing a - Potential disruption of
Slide 22: CONTACT: Stephanie Prince PCG Advisory
CONTACT: Stephanie Prince PCG Advisory (646) 863-6341 sprince@pcgadvisory.com